RxDoctor Payments Data

Kelsey Hocker, NP

Family · Durango, CONPI 1922549856

Payments from drug & device makers

$981in general payments, 2019–2025

Across 30 payments — averaging $32.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$206
  • Medtronic$150
  • KARL Storz Endoscopy-america$104
  • Myriad Genetic Laboratories, Inc.$99
  • Ferring Pharmaceuticals Inc.$67
  • 180 Medical, Inc.$58
  • plus $297 from 9 others

What the payments were for

  • Food & beverage$981100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 75th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$112,611
Medicare patients
512
Services billed
2,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron94$96,021
GemtesaVibegron14$14,400
Estradiol83$5,773
Tamsulosin Hcl393$5,523
Dutasteride77$3,197
Fosfomycin Tromethamine13$2,879
Finasteride192$2,752
Alfuzosin Hcl ErAlfuzosin Hcl106$2,376
Testosterone12$1,552
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst72$1,374
Oxybutynin Chloride ErOxybutynin Chloride74$1,006
ProgesteroneProgesterone, Micronized13$953
Testosterone Cypionate31$864
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$208
Cephalexin44$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$27$96,02194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,182 family providers in Colorado.

Other family in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →